• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    Director Geiger Uri bought $723,999 worth of shares (230,573 units at $3.14) (SEC Form 4)

    7/17/24 5:08:57 PM ET
    $SSKN
    Medical/Dental Instruments
    Health Care
    Get the next $SSKN alert in real time by email
    SEC FORM 4 SEC Form 4
    FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

    Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
    or Section 30(h) of the Investment Company Act of 1940
    OMB APPROVAL
    OMB Number: 3235-0287
    Estimated average burden
    hours per response: 0.5
      
    Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
      
    Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
    1. Name and Address of Reporting Person*
    Geiger Uri

    (Last) (First) (Middle)
    C/O STRATA SKIN SCIENCES, INC.
    5 WALNUT GROVE DRIVE, SUITE 140

    (Street)
    HORSHAM PA 19044

    (City) (State) (Zip)
    2. Issuer Name and Ticker or Trading Symbol
    STRATA Skin Sciences, Inc. [ SSKN ]
    5. Relationship of Reporting Person(s) to Issuer
    (Check all applicable)
    X Director X 10% Owner
    Officer (give title below) Other (specify below)
    3. Date of Earliest Transaction (Month/Day/Year)
    07/15/2024
    4. If Amendment, Date of Original Filed (Month/Day/Year)
    6. Individual or Joint/Group Filing (Check Applicable Line)
    X Form filed by One Reporting Person
    Form filed by More than One Reporting Person
    Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
    1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V Amount (A) or (D) Price
    Common Stock 07/15/2024 P 230,573 A $3.14 1,441,835 I See footnote(1)
    Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
    (e.g., puts, calls, warrants, options, convertible securities)
    1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
    Explanation of Responses:
    1. Shares are held directly by Accelmed Partners, L.P. The reporting person is the controlling member and managing partner of Accelmed Growth Partners (AGP) Limited, which is the general partner of Accelmed Partners (GP), L.P., which is the general partner of Accelmed Partners, L.P. and as a result he may be deemed to beneficially own the shares of common stock held by Accelmed Partners, L.P. The reporting person is the controlling shareholder and managing partner of Accelmed Growth Partners Management Ltd., which has certain voting and dispositive power over the shares of common stock owned by Accelmed Partners, L.P. pursuant to a management agreement, and as a result the reporting person may be deemed to beneficially own the shares of the common stock held by Accelmed Partners, L.P. The reporting person disclaims such beneficial ownership except to the extent of his pecuniary interest therein.
    /s/ Uri Geiger 07/17/2024
    ** Signature of Reporting Person Date
    Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
    * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
    ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
    Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
    Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
    Get the next $SSKN alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $SSKN

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $SSKN
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • STRATA Skin Sciences Reports First Quarter 2025 Financial Results and Provides a Corporate Update

      HORSHAM, Pa., May 14, 2025 (GLOBE NEWSWIRE) -- STRATA Skin Sciences, Inc. ("STRATA" or the "Company") (NASDAQ:SSKN), a medical technology company dedicated to developing, commercializing, and marketing innovative products for the treatment of dermatologic conditions, announces its financial results for the quarter ended March 31, 2025, and provides a corporate update. First Quarter 2025 Financial Highlights Revenue in the first quarter of 2025 was $6.8 million, up 1% Global net recurring XTRAC® revenue in the first quarter was $4.5 million vs. $4.6 million in the prior year period, with international growth of 27% offsetting a 4% decline in the domestic marketAverage net revenue per dome

      5/14/25 4:05:00 PM ET
      $SSKN
      Medical/Dental Instruments
      Health Care
    • STRATA Skin Sciences to Participate in the D. Boral Capital Inaugural Global Conference

      HORSHAM, Pa., May 08, 2025 (GLOBE NEWSWIRE) -- STRATA Skin Sciences, Inc. ("STRATA" or the "Company") (NASDAQ:SSKN), a medical technology company dedicated to developing, commercializing, and marketing innovative products for the treatment of dermatologic conditions, announces that it will participate in the D. Boral Capital Inaugural Global Conference. The conference is being held on May 14, 2025, at The Plaza Hotel, 768 Fifth Avenue, New York, NY 10019. President and Chief Executive Officer Dr. Dolev Rafaeli will be hosting one-on-one meetings on May 14, 2025 from 9:00 AM to 3:00 PM (ET). To register for one-on-one meetings with management at The Plaza Hotel in New York City, intereste

      5/8/25 8:15:00 AM ET
      $SSKN
      Medical/Dental Instruments
      Health Care
    • STRATA Skin Sciences to Report First Quarter 2025 Financial Results on May 14, 2025 and Provide Corporate Update

      HORSHAM, Pa., May 07, 2025 (GLOBE NEWSWIRE) -- STRATA Skin Sciences, Inc. ("STRATA" or the "Company") (NASDAQ:SSKN), a medical technology company dedicated to developing, commercializing, and marketing innovative products for the treatment of dermatologic conditions, announces that it will report first quarter 2025 financial results on Wednesday, May 14, 2025 after the market close. STRATA management will subsequently host a conference call at 5:00 p.m. ET on Wednesday, May 14, 2025 to review financial results and provide an update on corporate developments. Following management's formal remarks, there will be a question-and-answer session. To listen to the conference call, interested pa

      5/7/25 8:15:00 AM ET
      $SSKN
      Medical/Dental Instruments
      Health Care

    $SSKN
    Leadership Updates

    Live Leadership Updates

    See more
    • Apyx Medical Corporation Appoints Matthew Hill as Chief Financial Officer

      Apyx Medical Corporation (NASDAQ:APYX) ("Apyx Medical;" the "Company"), the manufacturer of a proprietary helium plasma and radiofrequency technology marketed and sold as Renuvion®, today announced the appointment of Matthew Hill to the position of Chief Financial Officer, effective December 4, 2023. Mr. Hill succeeds Tara Semb, whose departure was announced by the Company on November 9, 2023. "Matt joins our executive leadership team with over 30 years of financial and operational experience, more than 20 years of which has been in the healthcare industry, where he has served as the Chief Financial Officer of four publicly-traded healthcare companies," said Charlie Goodwin, President and

      11/28/23 8:30:00 AM ET
      $APYX
      $PDSB
      $SSKN
      Medical/Dental Instruments
      Health Care
      Biotechnology: Pharmaceutical Preparations
    • STRATA Skin Sciences Appoints Dr. Uri Geiger to Chairman of its Board of Directors

      HORSHAM, Pa., June 30, 2023 (GLOBE NEWSWIRE) -- STRATA Skin Sciences, Inc. (NASDAQ:SSKN), a medical technology company dedicated to developing, commercializing and marketing innovative products for the treatment of dermatologic conditions, today announced the appointment of Dr. Uri Geiger as the Chairman of the Board of Directors. William Humphries will step down as Chairman and continue to serve on the Board, effective July 3, 2023, as he transitions into his role as Chief Executive Officer of Alcami Corporation. "I'm honored to assume the role of Chairman at this pivotal moment in STRATA's growth," said Dr. Uri Geiger, Chairman of STRATA's Board of Directors. "I look forward to levera

      6/30/23 8:00:00 AM ET
      $SSKN
      Medical/Dental Instruments
      Health Care
    • STRATA Skin Sciences Appoints Patricia S. Walker, M.D., Ph.D. to its Board of Directors

      HORSHAM, Pa., Feb. 14, 2022 (GLOBE NEWSWIRE) -- STRATA Skin Sciences, Inc. (NASDAQ:SSKN), a medical technology company dedicated to developing, commercializing and marketing innovative products for the treatment of dermatologic conditions, announced that effective today, Patricia S. Walker M.D., PhD. has been appointed to its Board of Directors. Dr. Walker's vast experience includes more than 35 years as a practicing dermatologist and as a corporate leader in the medical dermatology, medical aesthetics and pharmaceutical industries, executing clinical research and strategic initiatives for a wide range of companies and educational institutions. "We are delighted to welcome Patty to STRAT

      2/14/22 4:05:00 PM ET
      $SSKN
      Medical/Dental Instruments
      Health Care

    $SSKN
    Financials

    Live finance-specific insights

    See more
    • STRATA Skin Sciences Reports First Quarter 2025 Financial Results and Provides a Corporate Update

      HORSHAM, Pa., May 14, 2025 (GLOBE NEWSWIRE) -- STRATA Skin Sciences, Inc. ("STRATA" or the "Company") (NASDAQ:SSKN), a medical technology company dedicated to developing, commercializing, and marketing innovative products for the treatment of dermatologic conditions, announces its financial results for the quarter ended March 31, 2025, and provides a corporate update. First Quarter 2025 Financial Highlights Revenue in the first quarter of 2025 was $6.8 million, up 1% Global net recurring XTRAC® revenue in the first quarter was $4.5 million vs. $4.6 million in the prior year period, with international growth of 27% offsetting a 4% decline in the domestic marketAverage net revenue per dome

      5/14/25 4:05:00 PM ET
      $SSKN
      Medical/Dental Instruments
      Health Care
    • STRATA Skin Sciences to Report First Quarter 2025 Financial Results on May 14, 2025 and Provide Corporate Update

      HORSHAM, Pa., May 07, 2025 (GLOBE NEWSWIRE) -- STRATA Skin Sciences, Inc. ("STRATA" or the "Company") (NASDAQ:SSKN), a medical technology company dedicated to developing, commercializing, and marketing innovative products for the treatment of dermatologic conditions, announces that it will report first quarter 2025 financial results on Wednesday, May 14, 2025 after the market close. STRATA management will subsequently host a conference call at 5:00 p.m. ET on Wednesday, May 14, 2025 to review financial results and provide an update on corporate developments. Following management's formal remarks, there will be a question-and-answer session. To listen to the conference call, interested pa

      5/7/25 8:15:00 AM ET
      $SSKN
      Medical/Dental Instruments
      Health Care
    • STRATA Skin Sciences to Report Fourth Quarter and Year End 2024 Financial Results on March 27, 2025 and Provide Corporate Update

      HORSHAM, Pa., March 21, 2025 (GLOBE NEWSWIRE) -- STRATA Skin Sciences, Inc. ("STRATA" or the "Company") (NASDAQ:SSKN), a medical technology company dedicated to developing, commercializing, and marketing innovative products for the treatment of dermatologic conditions, announces that it will report fourth quarter and year end 2024 financial results on Thursday, March 27, 2025 after the market close. STRATA management will host a conference call at 4:30 p.m. ET on Thursday, March 27, 2025 to review financial results and provide an update on corporate developments. Following management's formal remarks, there will be a question-and-answer session. To listen to the conference call, interest

      3/21/25 1:43:43 PM ET
      $SSKN
      Medical/Dental Instruments
      Health Care

    $SSKN
    SEC Filings

    See more
    • Strata Skin Sciences Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits

      8-K - STRATA Skin Sciences, Inc. (0001051514) (Filer)

      5/14/25 5:25:17 PM ET
      $SSKN
      Medical/Dental Instruments
      Health Care
    • Amendment: SEC Form 10-K/A filed by Strata Skin Sciences Inc.

      10-K/A - STRATA Skin Sciences, Inc. (0001051514) (Filer)

      4/30/25 4:33:20 PM ET
      $SSKN
      Medical/Dental Instruments
      Health Care
    • Strata Skin Sciences Inc. filed SEC Form 8-K: Changes in Registrant's Certifying Accountant, Financial Statements and Exhibits

      8-K - STRATA Skin Sciences, Inc. (0001051514) (Filer)

      4/25/25 4:30:45 PM ET
      $SSKN
      Medical/Dental Instruments
      Health Care

    $SSKN
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Geiger Uri bought $723,999 worth of shares (230,573 units at $3.14) (SEC Form 4)

      4 - STRATA Skin Sciences, Inc. (0001051514) (Issuer)

      7/17/24 5:08:57 PM ET
      $SSKN
      Medical/Dental Instruments
      Health Care
    • Large owner Accelmed Partners, L.P. bought $723,999 worth of shares (230,573 units at $3.14), increasing direct ownership by 19% to 1,441,835 units (SEC Form 4)

      4 - STRATA Skin Sciences, Inc. (0001051514) (Issuer)

      7/17/24 5:08:11 PM ET
      $SSKN
      Medical/Dental Instruments
      Health Care
    • Chief Executive Officer Rafaeli Dolev bought $59,974 worth of shares (19,100 units at $3.14), increasing direct ownership by 15% to 143,156 units (SEC Form 4)

      4 - STRATA Skin Sciences, Inc. (0001051514) (Issuer)

      7/17/24 5:01:09 PM ET
      $SSKN
      Medical/Dental Instruments
      Health Care

    $SSKN
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by Chief Operating Officer Gov Shmuel

      4 - STRATA Skin Sciences, Inc. (0001051514) (Issuer)

      5/15/25 5:21:12 PM ET
      $SSKN
      Medical/Dental Instruments
      Health Care
    • SEC Form 4 filed by Chief Accounting Officer Gillings John T

      4 - STRATA Skin Sciences, Inc. (0001051514) (Issuer)

      5/15/25 5:14:28 PM ET
      $SSKN
      Medical/Dental Instruments
      Health Care
    • SEC Form 4 filed by Chief Executive Officer Rafaeli Dolev

      4 - STRATA Skin Sciences, Inc. (0001051514) (Issuer)

      5/15/25 5:09:40 PM ET
      $SSKN
      Medical/Dental Instruments
      Health Care

    $SSKN
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Strata Skin Sciences Inc.

      SC 13G/A - STRATA Skin Sciences, Inc. (0001051514) (Subject)

      11/14/24 2:04:43 PM ET
      $SSKN
      Medical/Dental Instruments
      Health Care
    • Amendment: SEC Form SC 13D/A filed by Strata Skin Sciences Inc.

      SC 13D/A - STRATA Skin Sciences, Inc. (0001051514) (Subject)

      7/18/24 7:42:09 PM ET
      $SSKN
      Medical/Dental Instruments
      Health Care
    • SEC Form SC 13G/A filed by Strata Skin Sciences Inc. (Amendment)

      SC 13G/A - STRATA Skin Sciences, Inc. (0001051514) (Subject)

      2/14/24 4:51:41 PM ET
      $SSKN
      Medical/Dental Instruments
      Health Care